High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

• Published in: Blood 2011-11, Vol.118 (21), p.630-630
• Main Authors: Paiva, Bruno, Gutierrez, Norma C., Rosiñol, Laura, Vidriales, María-Belén, Montalbán, María-Angeles, Martínez-López, Joaquín, Mateos, Maria Victoria, Cibeira, María Teresa, Courdón, Lourdes, Oriol, Albert, Terol, María José, Echebeste, Maria-Asuncion, de Paz, Raquel, de Arriba, Felipe, Palomera, Luis, De La Rubia, Javier, Díaz-Mediavilla, Joaquín, Sureda, Anna, Gorosquieta, Ana, Alegre, Adrian, Martín, Alejandro, Hernandez, Miguel T., Lahuerta, Juan José, Blade, Joan, Miguel, Jesus F. San
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V118.21.630.630

Abstract 630▪▪This icon denotes a clinically relevant abstract The achievement of CR after high-dose therapy/ASCT (HDT/ASCT) is a surrogate for prolonged survival in MM. While this is well accepted, the long-term clinical outcome of MM patients achieving CR is still heterogeneous and a small fraction of patients unexpectedly lose their CR status early on after HDT/ASCT and experience a dismal survival. In fact, survival of patients with unsustained CR is even poorer than that of those not achieving CR. Herein we sought to identify prognostic markers predictive of unsustained CR after HDT/ASCT. The study included a total of 241 patients achieving CR at day+100 after HDT/ASCT treated in two consecutive GEM/PETHEMA trials: GEM2000 (VBMCP/VBAD, n=140) and GEM2005